Package Leaflet: Information for the User
Solifenacin succinate 10 mg film-coated tablets EFG
Solifenacin succinate
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
If you have any questions, ask your doctor or pharmacist.
5Storage of solifenacin succinate
6.Contents of the pack and other information
The active ingredient of solifenacina cinfa belongs to the group of anticholinergics. These medications are used to reduce the activity of an overactive bladder. This allows you to have more time before needing to go to the bathroom and increases the amount of urine that your bladder can hold.
Solifenacina cinfa is used to treat the symptoms of overactive bladder syndrome. These symptoms include: having a strong and sudden need to urinate without prior warning, having to urinate frequently or having urine leakage because you did not make it to the bathroom on time.
Do not take solifenacina cinfa
Inform your doctor if you have or have had any of the diseases mentioned above before starting treatment with solifenacina.
Warnings and precautions
Consult your doctor or pharmacist before starting to take solifenacina
Children and adolescents
Inform your doctor before starting treatment with solifenacina, if any of the circumstances mentioned above have occurred at any time.
Solifenacina should not be used in children or adolescents under 18 years old.
Before starting treatment with solifenacina, your doctor will assess whether there are other causes for your need to urinate frequently (e.g. heart failure or kidney disease). If you have a urinary tract infection, your doctor will prescribe an antibiotic (a treatment for certain bacterial infections).
Taking solifenacina cinfa with other medicines
Inform your doctor or pharmacist if you are taking or have recently taken any other medicine.
It is especially important to inform your doctor if you are taking:
Taking solifenacina cinfa with food and drinks
Solifenacina cinfa can be taken with or without food, as you prefer.
Pregnancy, breastfeeding, and fertility
You should not use solifenacina if you are pregnant, unless absolutely necessary. Do not use solifenacina during breastfeeding, as solifenacina may pass into breast milk.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and operating machinery
Solifenacina may cause blurred vision and sometimes drowsiness or fatigue. If you experience any of these side effects, do not drive or operate machinery.
Instructions for correct use
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Swallow the entire tablet with some liquid. You can take it with or without food, according to your preference. Do not crush the tablets.
The usual dose is 5 mg per day, unless your doctor tells you to take 10 mg per day.
If you take more solifenacin cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
The symptoms in case of overdose may include: headache, dry mouth, dizziness, drowsiness, and blurred vision, perception of things that are not there (hallucinations), pronounced excitement, convulsions, difficulty breathing, increased heart rate (tachycardia), urine accumulation in the bladder (urinary retention), and dilation of the pupils (mydriasis).
If you forget to take solifenacin cinfa
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take the next dose. Never take more than one dose per day.
If you interrupt treatment with solifenacin cinfa
If you stop taking solifenacin cinfa, your overactive bladder symptoms may return or worsen. Always consult your doctor if you are thinking of interrupting treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If you experience an allergic attack or a severe skin reaction (such as blistering and peeling of the skin), you must inform your doctor or nurse immediately.
Angioedema (allergy on the skin resulting in inflammation that occurs in the tissue beneath the skin surface) with respiratory tract obstruction (difficulty breathing) has been reported in some patients treated with solifenacin succinate. If angioedema appears, treatment with solifenacin succinate must be stopped immediately and appropriate treatment and/or measures must be taken.
Solifenacin cinfa may cause the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Unknown frequency (frequency cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30 °C..
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need.By doing so, you will help protect the environment.
Compositionof solifenacin cinfa
Appearance of the product and contents of the packaging
Solifenacin cinfa 10 mg tablets are rough, cylindrical, biconvex, pale pink, unnotched tablets with the logo “S1” on one face.
Solifenacin cinfa 10 mg tablets are supplied in blisters of 30 tablets.
Holder of the marketing authorization and responsible manufacturer
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta.
31620 Huarte (Navarra) - Spain
Date of the last review of this leaflet:April 2018
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
You can access detailed and updated information about this medication by scanning with your mobile phone (smartphone) the QR code included in the leaflet and packaging. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/83023/P_83023.html
QR code to:https://cima.aemps.es/cima/dochtml/p/83023/P_83023.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.